Associated Papers
Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.
Oehler VG et al.
Leukemia, 2026
Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.
Jung Y et al.
Nature Biomedical Engineering, 2025
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report.
Zhou X et al.
Oncology Letters, 2025
Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients.
Dung PC et al.
Leukemia Research Reports, 2025
BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d'Ivoire.
Koffi KG et al.
Leukemia Research Reports, 2025
Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.
Yusoff YM et al.
The Malaysian Journal of Pathology, 2024
A Novel Next-Generation Sequencing Assay for the Identification of BCR::ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations.
Yan Z et al.
The Journal of Applied Laboratory Medicine, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Innes AJ et al.
Leukemia, 2024
Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort.
Chaudhary P et al.
Scientific Reports, 2024
Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA et al.
Bmc Research Notes, 2024
BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India.
S A et al.
Leukemia Research Reports, 2024
Next-generation sequencing-based analysis to assess the pattern of relapse in patients with Philadelphia-positive acute lymphoblastic leukemia.
Ahn JS et al.
Ejhaem, 2022
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R et al.
Scientific Reports, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D et al.
Critical Reviews in Oncology/hematology, 2022
Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing.
Abulaiti D et al.
Cytogenetic and Genome Research, 2022
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A et al.
Life (basel, Switzerland), 2021
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
Romzova M et al.
British Journal of Haematology, 2021
In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy.
Heatley SL et al.
Leukemia & Lymphoma, 2021
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S et al.
British Journal of Haematology, 2021
Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.
Curik N et al.
Frontiers in Oncology, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis.
Liu J et al.
Oncology Letters, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G et al.
Cancer Medicine, 2019
Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations.
Xue M et al.
International Journal of Laboratory Hematology, 2019
Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias.
Schmitt MW et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia.
Kim H et al.
Clinical Lymphoma, Myeloma & Leukemia, 2018
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Naqvi K et al.
International Journal of Hematology, 2018
A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.
Vinhas R et al.
Oncotargets and Therapy, 2018
Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.
Minervini CF et al.
Experimental and Molecular Pathology, 2017
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
Tsubaki M et al.
Oncotarget, 2017
The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
Kayastha GK et al.
British Journal of Haematology, 2017
[Mutations in the BCR-ABL1 gene in a peruvian patient with acute lymphoblastic leukemia resistant to therapy].
Ortiz CA et al.
Revista De La Facultad De Ciencias Medicas (cordoba, Argentina), 2017
Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
Miyamura K et al.
Leukemia Research, 2016
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
Baer C et al.
Haematologica, 2016
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Deininger MW et al.
Blood, 2016
[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].
Cai W et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2016
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
Zabriskie MS et al.
Leukemia, 2015
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS et al.
Cancer Cell, 2014
Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
Ai J et al.
Therapeutic Advances in Hematology, 2014
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S et al.
Leukemia Research, 2014